Pharmacotherapy of canine atopic dermatitis-current state and new trends

Abstract

This review offers a concise overview of current treatment options for canine atopic dermatitis and provide an outline of two promising new treatment options (phosphodiesterase 4 and histamine H4 receptor inhibitors). Glucocorticoids have been one of the first successful treatment options and are still part of the treatment regime. Ciclosporin was introduced more than 15 years ago and is also a main pharmacological treatment option. In 2013, the Janus kinase inhibitor oclacitinib was introduced as a first in class, which is then followed by the anti-canine IL-31 antibody lokivetmab in 2016. Thus, exciting new treatment options have found their way into clinical practice. Apart from these substance classes, antihistamines, essential fatty acids and lipid substitution will be discussed as add-on treatments.